Please find enclosed herewith un-audiited financial results for the quarter and half year ended on 30th September 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd has published its standalone unaudited financial results for the quarter and half year ended 30 September 2025 in English (Financial Express) and Hindi (Jansatta) newspapers, as required under SEBI listing rules. Total income from operations for Q2 FY26 stood at Rs. 9,00,000, unchanged from the previous quarter (Q1 FY26) but sharply lower than Rs. 20,50,000 in the same quarter last year. Net profit after tax for the quarter was just Rs. 33,049, down from Rs. 2,46,531 in Q1 FY26 and Rs. 14,75,637 in Q2 FY25. Basic and diluted EPS for the quarter was Rs. 0.01 versus Rs. 0.48 a year ago. The Board took the results on record on 15 October 2025 after a limited review by the statutory auditor.
This is a routine compliance filing (newspaper publication) rather than new information, but the underlying numbers point to a very small, shrinking business with revenue and profits falling sharply year-on-year. Shareholders should note the steep YoY decline in both revenue and profitability, which could weigh on sentiment given the company's micro-cap scale.